Review



human ril-2  (PeproTech)


Bioz Verified Symbol PeproTech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    PeproTech human ril-2
    Human Ril 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/ril+2+cytokine/pm39701104-306-66-70
    Average 90 stars, based on 1 article reviews
    human ril-2 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Clone Assay:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Isolation:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Generated:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Flow Cytometry:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Irradiation:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Cell Culture:

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells.
    Article Snippet: RESEARCH ARTICLE | APRIL 29 2024 Polyclonally Derived Alloantigen-Speci c T Regulatory Cells Exhibit Target- Speci c Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya; ... et. al J Immunol (2024) 212 (12): 1891–1903. https://doi.org/10.4049/jimmunol.2300780 Related Content Antigen-speci c induced T regulatory cells (iTregs) inhibit dendritic cell (DC) function by capturing peptide-MHCII complexes from the DC surface J Immunol (May,2016) D ow nloaded from http://journals.aai.org/jim m unol/article-pdf/212/12/1891/1657863/ji2300780.pdf by guest on 12 M ay 2025 Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells Yoshihiro Oya,*,†,‡ Yasuyo Tanaka,* Takuya Nakazawa,‡ Ryutaro Matsumura,‡

    Article Title: Promiscuous recognition of MR1 drives self-reactive mucosal-associated invariant T cell responses.
    Article Snippet: Human rIL-2 (5 IU/ml; Peprotech) was added at day 5 and thereafter every 2 d. Cells were washed and rechallenged as indicated (ratio 2:1) in the presence or absence of purified anti-MR1 mAb (20 μg/ml, Ultra-LEAF Purified Clone 26.5; BioLegend).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: One suitable medium for culturing primary human CD3+ T cells includes 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: HIV-1 protective epitope-specific CD8 + T cells in HIV-1-exposed seronegative individuals
    Article Snippet: 3×10 5 or 6×10 5 PBMCs were stimulated with 1 μM concentrations of the corresponding peptides and then cultured for 3 weeks in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% FCS, 10 ng/mL of human rIL-2 (PeproTech, Cranbury, NJ, USA), x1 MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mM sodium pyruvate solution (Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: Nuclease-mediated genome editing of primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).

    Article Title: The carbonyl nucleobase adduct M 3 Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells.
    Article Snippet: Primary cell lines and clones used in this study were isolated from PBMCs obtained using Lymphoprep (StemCell Technologies) from the peripheral blood of blood bank donors andmaintained in culture as previously described.9 MR1-M3Ade-specific T cell lines were generated by one of three methods. i) Direct sorting by flow cytometry of MR1-M3Ade tetramer-positive cells from PBMCs followed by either stimulation with phytohaemagglutinin (PHA, 1 mg/mL, Remel, HA16) human rIL-2 (100 U/mL, Peprotech) and irradiated PBMCs (53105 cells/mL), or cloning by limiting dilution. ii) Expansion of specific T cells from CD3+ enriched PBMCs pre-labeled with Cell Trace Violet according to the manufacturer’s instructions and stimulated with irradiated (80 Gray) A375b-MR1 cells (ratio 2:1).

    Article Title: Pharmaceutical compositions comprising gene-corrected primary cells
    Article Snippet: CD3+ T cells were cultured in X-VIVO 15 (Lonza, Walkersville, Md., USA) containing 5% human serum (Sigma-Aldrich, St. Louis, Mo., USA), 10 ng/ml human rIL-7 (BD Biosciences, San Jose, Calif., USA), and 100 IU/ml human rIL-2 (Peprotech, Rocky Hill, N.J., USA).



    Similar Products

    recombinant il 2 ril 2  (Miltenyi Biotec)
    96
    Miltenyi Biotec recombinant il 2 ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Il 2 Ril 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Human+IL-2+IS%2C+research+grade/med_rxiv__64898__2026__05__30__26354518-212-13-17
    Average 96 stars, based on 1 article reviews
    recombinant il 2 ril 2 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    ril 2  (Miltenyi Biotec)
    96
    Miltenyi Biotec ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Ril 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Human+IL-2+IS%2C+premium+grade/10__31083_slash_fbl51459-86-16-22
    Average 96 stars, based on 1 article reviews
    ril 2 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    ril 2  (R&D Systems)
    95
    R&D Systems ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Ril 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Recombinant+Human+IL-2+Protein%2C+CF/pmc13057379-123-99-103
    Average 95 stars, based on 1 article reviews
    ril 2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    recombinant interleukin 2 ril 2  (Thermo Fisher)
    95
    Thermo Fisher recombinant interleukin 2 ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Interleukin 2 Ril 2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Interleukin+2%2C+human/pm41462459-88-28-24
    Average 95 stars, based on 1 article reviews
    recombinant interleukin 2 ril 2 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    human ril 2  (Miltenyi Biotec)
    96
    Miltenyi Biotec human ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Human Ril 2, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Human+IL-2+IS%2C+research+grade/pmc09552804__mmc5-342-54-56
    Average 96 stars, based on 1 article reviews
    human ril 2 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    human ril-2  (PeproTech)
    90
    PeproTech human ril-2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Human Ril 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/ril+2+cytokine/pm39701104-306-66-70
    Average 90 stars, based on 1 article reviews
    human ril-2 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    recombinant proteins ril 2 r d systems  (R&D Systems)
    92
    R&D Systems recombinant proteins ril 2 r d systems
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Proteins Ril 2 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Recombinant+Human+IBSP%2FSialoprotein+II+Protein%2C+CF/pm39178841-631-192-195
    Average 92 stars, based on 1 article reviews
    recombinant proteins ril 2 r d systems - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    recombinant human interleukin (ril)-2  (R&D Systems Hematology)
    90
    R&D Systems Hematology recombinant human interleukin (ril)-2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Recombinant Human Interleukin (Ril) 2, supplied by R&D Systems Hematology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/interleukin+2++il+2/pmc11380426-34-22-26
    Average 90 stars, based on 1 article reviews
    recombinant human interleukin (ril)-2 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    human ril 2  (R&D Systems)
    96
    R&D Systems human ril 2
    Plasma <t>level</t> <t>IL-2</t> in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.
    Human Ril 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+ril-2/Recombinant+Human+IL-2+Protein/pm39115541-221-7-10
    Average 96 stars, based on 1 article reviews
    human ril 2 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Plasma level IL-2 in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.

    Journal: medRxiv

    Article Title: Targeting PTP1B and DUSP4 phosphatases to Boost Tregs: A Novel Therapy for Polyendocrine Metabolic Ovarian Syndrome (PMOS) Immune Dysfunction

    doi: 10.64898/2026.05.30.26354518

    Figure Lengend Snippet: Plasma level IL-2 in control (n=37) and PMOS (n=37) subjects and altered gene expression of JAKs in the total leukocyte RNA of 102 control and 102 PMOS subjects. A: Dot plot graphical representation of IL-2 level in the control and PMOS subjects. B-D: Dot and violin plot graphical representation of real-time gene expression level in JAK1, JAK2 and JAK3 . Each dot represents an individual subject. Each reaction was performed in triplicates and the ΔCt method was used to calculate the gene expression difference between control and PMOS subjects. 2 −ΔCt values of each subject are plotted on the Y-axis of the graph. Unpaired student’s T-tests were performed using GraphPad Prism 8 and p-value< 0.05 were set to be significant. Graph E and F: Dot and bar graph representation of relative gene expression level of JAK1, and JAK2 among the control and PMOS phenotype A, B, C, and D. The control group represented black dots, phenotype A in blue dots, phenotype B in orange dots, phenotype C in violet dots and phenotype D in yellow dots. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were set to be statistically significant.

    Article Snippet: After 24 hours of siRNA treatment, the cells were stimulated with 300IU of recombinant IL-2 (rIL-2) (#130-097-743, Miltenyi Biotech, Germany).

    Techniques: Clinical Proteomics, Control, Gene Expression

    FACS analysis showed an increase of CD4 +ve CD25 +ve CD127 low/- Treg population after PTP1B and DUSP4 (MKP-2) siRNA-based knockdown in PBMCs of PMOS (n=12) subjects. A: bar graph representation showing the gene expression of PTP1B and DUSP4 across the PTP1B, DUSP4, and both silenced PBMCs. B: Dot plot and histogram representation of gating strategy with P1 shows lymphocyte population, P2 shows CD4-FITC +ve population, P3 shows CD25-PE Cy7 +ve population and P4 shows CD127 low/- Treg population. Gating is based on histogram of unstained and stained population (FITC, PE Cy7 and Alexa Fluor 647 respectively). C: Dot plot representation of CD4-FITC +ve CD25-PECy7 +ve CD127-Alexa Fluor 647 low/- (P4) Treg population of all treatment conditions including; untreated, IL-2 treated, control siRNA silenced, control siRNA silenced with IL-2, PTP1B siRNA silenced without IL-2 and with IL-2, DUSP4 siRNA silenced without IL-2 and with IL-2, and PTP1B+DUSP4 siRNA silenced without IL-2 and with IL-2. D: Dot and truncated violin plot representation of the percentage of CD4 +ve CD25 +ve CD127 low/- Treg population in lymphocyte events across all the treatments. Each dot represents an individual subject. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were considered as statistically significant.

    Journal: medRxiv

    Article Title: Targeting PTP1B and DUSP4 phosphatases to Boost Tregs: A Novel Therapy for Polyendocrine Metabolic Ovarian Syndrome (PMOS) Immune Dysfunction

    doi: 10.64898/2026.05.30.26354518

    Figure Lengend Snippet: FACS analysis showed an increase of CD4 +ve CD25 +ve CD127 low/- Treg population after PTP1B and DUSP4 (MKP-2) siRNA-based knockdown in PBMCs of PMOS (n=12) subjects. A: bar graph representation showing the gene expression of PTP1B and DUSP4 across the PTP1B, DUSP4, and both silenced PBMCs. B: Dot plot and histogram representation of gating strategy with P1 shows lymphocyte population, P2 shows CD4-FITC +ve population, P3 shows CD25-PE Cy7 +ve population and P4 shows CD127 low/- Treg population. Gating is based on histogram of unstained and stained population (FITC, PE Cy7 and Alexa Fluor 647 respectively). C: Dot plot representation of CD4-FITC +ve CD25-PECy7 +ve CD127-Alexa Fluor 647 low/- (P4) Treg population of all treatment conditions including; untreated, IL-2 treated, control siRNA silenced, control siRNA silenced with IL-2, PTP1B siRNA silenced without IL-2 and with IL-2, DUSP4 siRNA silenced without IL-2 and with IL-2, and PTP1B+DUSP4 siRNA silenced without IL-2 and with IL-2. D: Dot and truncated violin plot representation of the percentage of CD4 +ve CD25 +ve CD127 low/- Treg population in lymphocyte events across all the treatments. Each dot represents an individual subject. One-way ANOVA was performed using GraphPad Prism 8 and p-value< 0.05 were considered as statistically significant.

    Article Snippet: After 24 hours of siRNA treatment, the cells were stimulated with 300IU of recombinant IL-2 (rIL-2) (#130-097-743, Miltenyi Biotech, Germany).

    Techniques: Knockdown, Gene Expression, Staining, Control